TY - JOUR
T1 - Physostigmine and cognition in schizotypal personality disorder
AU - Kirrane, Richelle M.
AU - Mitropoulou, Vivian
AU - Nunn, Melissa
AU - Silverman, Jeremy
AU - Siever, Larry J.
N1 - Funding Information:
This work was supported in part by a VA Merit Award to Dr. Siever and Grant 5 MO1 RR00071 for the Mount Sinai General Clinical Research Center from The National Center for Research Resources, NIH.
PY - 2001/3/1
Y1 - 2001/3/1
N2 - There is evidence that reduced cholinergic activity may play a role in the pathophysiology of cognitive impairment in the schizophrenia spectrum. We tested the effects of physostigmine, an anticholinesterase inhibitor, on visuospatial working memory as evaluated by the Dot test, and on verbal learning and recall as measured by a serial learning task in patients with schizotypal personality disorder. Physostigmine tended to improve the Dot test, but not serial verbal learning performance in these patients.
AB - There is evidence that reduced cholinergic activity may play a role in the pathophysiology of cognitive impairment in the schizophrenia spectrum. We tested the effects of physostigmine, an anticholinesterase inhibitor, on visuospatial working memory as evaluated by the Dot test, and on verbal learning and recall as measured by a serial learning task in patients with schizotypal personality disorder. Physostigmine tended to improve the Dot test, but not serial verbal learning performance in these patients.
KW - Cognitive impairment
KW - Physostigmine
KW - Schizotypal personality disorder
UR - http://www.scopus.com/inward/record.url?scp=0035281005&partnerID=8YFLogxK
U2 - 10.1016/S0920-9964(00)00059-1
DO - 10.1016/S0920-9964(00)00059-1
M3 - Article
C2 - 11278149
AN - SCOPUS:0035281005
SN - 0920-9964
VL - 48
SP - 1
EP - 5
JO - Schizophrenia Research
JF - Schizophrenia Research
IS - 1
ER -